Home > Cardiology > EHRA 2022 > Updates on Ablation > First results of the POWER FAST III trial

First results of the POWER FAST III trial

Presented By
Prof. José Luis Merino, La Paz University Hospital, Spain
Presented by
José Luis Merino La Paz University Hospital
Conference
EHRA 2022
Trial
POWER FAST III
Doi
https://doi.org/10.55788/4a2f03fa
The first results of the POWER FAST III trial showed that the number of oesophageal lesions was similar in patients who received high-power short duration (HPSD) radio-frequency (RF) pulmonary vein isolation (PVI) ablation and in patients who were treated with a conventional low-power long duration (LPLD) radio-frequency (RF) PVI ablation. A recently published meta-analysis favoured HPSD PVI ablation over LPLD PVI ablation in terms of efficacy [1]. “However, this meta-analysis included mostly single-centre, non-randomised studies,” argued Prof. José Luis Merino (La Paz University Hospital, Spain) [2]. “Moreover, the rate of oesophageal injuries should be compared for the 2 treatment modalities.” The multicentre, randomised POWER FAST III trial (NCT04153747) included 267 patients with paroxysmal or persistent atrial fibrillation (AF), who were randomised 1:1 to rece...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on